These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 32668469)

  • 21. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH
    PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
    Badjatiya A; Rao SV
    Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Lamberts M; Olesen JB; Ruwald MH; Hansen CM; Karasoy D; Kristensen SL; Køber L; Torp-Pedersen C; Gislason GH; Hansen ML
    Circulation; 2012 Sep; 126(10):1185-93. PubMed ID: 22869839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
    Liu L; Huang J; Zhang X; Tang X
    PLoS One; 2018; 13(6):e0199232. PubMed ID: 29920547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Triska J; Haddadin F; Madanat L; Jabri A; Daher M; Birnbaum Y; Jneid H
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):605-619. PubMed ID: 35829979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
    Verburg A; Bor WL; Küçük IT; Henriques JPS; Vink MA; Ruifrok WT; Plomp J; Heestermans TACM; Schotborgh CE; Vlaar PJ; Magro M; Rikken SAOF; van den Broek WWA; van Mieghem CAG; Cornelis K; Rosseel L; Dujardin KS; Vandeloo B; Vandendriessche T; Ferdinande B; van 't Hof AWJ; Tijssen JGP; Limbruno U; De Caterina R; Rubboli A; Angiolillo DJ; Adriaenssens T; Dewilde W; Ten Berg JM
    EuroIntervention; 2024 Jul; 20(14):e898-e904. PubMed ID: 39007830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
    Gao X; Ge Z; Kong X; Wang Z; Zuo G; Wang F; Chen S; Zhang J
    Int Heart J; 2019 May; 60(3):546-553. PubMed ID: 31105152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
    Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
    Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
    Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    Lam DH; Bell SM; Hira RS
    Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.